Stocks

AmerisourceBergen (ABC) Soars 3.5%: Is Further Upside Left in the Stock?

AmerisourceBergen (ABC) shares soared 3.5% in the last trading session to close at $116.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.5% loss over the past four weeks.

AmerisourceBergen saw a strong price increase following the New York Attorney General Letitia James’ announcement of a $1.1 billion settlement agreement with three of the nation’s largest drug distributors. Interestingly, AmerisourceBergen is one these three companies. This in turn will help the New York State to fight the ongoing opioid epidemic.

This prescription drug distributor is expected to post quarterly earnings of $1.98 per share in its upcoming report, which represents a year-over-year change of +7%. Revenues are expected to be $51.47 billion, up 13.4% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For AmerisourceBergen, the consensus EPS estimate for the quarter has been revised 4.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ABC going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Click to get this free report

AmerisourceBergen Corporation (ABC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Investing

Latest Stocks Videos

    Weekly Performance in Stocks in a Volatile Week With Evergrande and Debt Ceiling Talk

    Sanctuary Wealth Chief Investment Officer Jeff Kilburg discusses weekly performance in stocks in what started out to be a volatile week with Evergrande and debt ceiling talk.

    3 days ago

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More